Generics & Biosimilars | Association for Accessible Medicines
  • ""
    Snooze + Lose
    Don't miss out on the limited number of discounted rooms available for the GRx+Biosims 2019 conference. Book your hotel today and attend this year's can't-miss conference.
  • ""
    How Much Did Your State Save?
    Take a deeper look at state-by-state generic drug savings from the 2019 Generic Drug and Biosimilars Access & Savings in the U.S. report.
  • NAFTA 2.0: Obstacles to More Affordable Medicines for Americans
    NAFTA 2.0: Obstacles to More Affordable Medicines
    The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!
  • 2019 AAM Access & Savings report - pills image
    AAM's 2019 Access & Savings in the U.S. Report
    The quality and affordability of generic medicines makes possible greater access, adherence and improved health for millions of patients across the United States.
  • ""
    Failure to Launch
    Although 20 biosimilars have been approved by the FDA in the U.S., only seven are currently commercially available. Learn how patent abuse blocks access to biosimilars for America's patients.
  • ""
    American Patients: Tell Congress to Fix the USMCA
    AAM’s Jonathan Kimball urges Americans to tell their member of Congress to stand up for patients and fix the USMCA trade agreement (NAFTA 2.0).

Recent Updates

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.